Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.55 |
| ▸ | JAK3 | P52333 | 7/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385021 | 1.00 | JAK2 (0.55) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4382086 | 0.89 | JAK2 (0.70) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4458801 | 0.81 | JAK2 (0.46) | JAK2JAK3JAK1TYK2CCNA2 | |
| SCHEMBL13588597 | 0.79 | JAK2 (0.44) | JAK2JAK3JAK1CCNA2CDK2 | |
| SCHEMBL4383238 | 0.78 | JAK2 (0.57) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4382407 | 0.78 | JAK2 (0.70) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4382402 | 0.78 | JAK2 (0.70) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4383067 | 0.74 | JAK2 (0.68) | JAK2JAK3IKBKBJAK1TYK2 | |
| SCHEMBL4377197 | 0.74 | JAK2 (0.57) | JAK2JAK3PDGFRBFLT3TBK1 | |
| SCHEMBL4380896 | 0.74 | JAK2 (0.55) | JAK2JAK3PDGFRBFLT3TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PDGFRB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.